Aled Williams
Director/Board Member at DESTINY PHARMA PLC
Net worth: 11 113 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Love | M | 62 | 28 years | |
| Debra Stephanie Barker | M | 61 | 4 years | |
| Shaun Claydon | M | 56 | 6 years | |
| Anthony Rudd | M | 76 | 13 years | |
| Nigel Brooksby | M | - | 2 years | |
| Christopher Tovey | M | 59 | 1 years | |
| Lisa Olson | M | 63 |
Enthera Srl
 Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | - |
| James Stearns | M | - | 2 years | |
| William Rhys-Williams | M | - | 26 years | |
| Jim Lees | M | - | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nick Rodgers | M | 65 | 5 years | |
| Neil Clark | M | 62 | 6 years | |
| Huai Zheng Peng | M | 62 | 5 years | |
| Stephanie Bewick | M | - | 2 years | |
| Behrad Derakhshan | M | 44 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 13 | 86.67% |
| Switzerland | 1 | 6.67% |
| Italy | 1 | 6.67% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Aled Williams
- Personal Network
